Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

RGS10 regulates the expression of Cyclooxygenase-2 and Tumor Necrosis Factor alpha through a G-protein-independent mechanism.

Alqinyah M, Almutairi F, Wendimu MY, Hooks S.

Mol Pharmacol. 2018 Jul 26. pii: mol.118.111674. doi: 10.1124/mol.118.111674. [Epub ahead of print]

2.

Regulating the regulators: Epigenetic, transcriptional, and post-translational regulation of RGS proteins.

Alqinyah M, Hooks SB.

Cell Signal. 2018 Jan;42:77-87. doi: 10.1016/j.cellsig.2017.10.007. Epub 2017 Oct 16. Review.

PMID:
29042285
3.

Sphingosine-1-Phosphate (S1P) Signaling in Neural Progenitors.

Callihan P, Alqinyah M, Hooks SB.

Methods Mol Biol. 2018;1697:141-151. doi: 10.1007/7651_2017_3.

PMID:
28361481
4.

Regulator of G Protein Signaling 10 (Rgs10) Expression Is Transcriptionally Silenced in Activated Microglia by Histone Deacetylase Activity.

Alqinyah M, Maganti N, Ali MW, Yadav R, Gao M, Cacan E, Weng HR, Greer SF, Hooks SB.

Mol Pharmacol. 2017 Mar;91(3):197-207. doi: 10.1124/mol.116.106963. Epub 2016 Dec 28.

5.

From the Battlefield to the Bedside: Supporting Warfighter and Civilian Health With the "ART" of Whole Genome Sequencing for Antibiotic Resistance and Outbreak Investigations.

Lesho E, Lin X, Clifford R, Snesrud E, Onmus-Leone F, Appalla L, Ong A, Maybank R, Nielsen L, Kwak Y, Hinkle M, Turco J, Marin JA, Hooks S, Matthews S, Hyland S, Little J, Waterman P, McGann P.

Mil Med. 2016 Jul;181(7):621-4. doi: 10.7205/MILMED-D-15-00197.

PMID:
27391613
6.

AMPKα1 knockout enhances nociceptive behaviors and spinal glutamatergic synaptic activities via production of reactive oxygen species in the spinal dorsal horn.

Maixner DW, Yan X, Hooks SB, Weng HR.

Neuroscience. 2016 Jun 21;326:158-169. doi: 10.1016/j.neuroscience.2016.03.061. Epub 2016 Apr 4.

7.

Cellular deficiency in the RGS10 protein facilitates chemoresistant ovarian cancer.

Hooks SB, Murph MM.

Future Med Chem. 2015 Aug;7(12):1483-9. doi: 10.4155/fmc.15.81. Epub 2015 Aug 21. Review.

8.

Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach.

Hung SW, Marrache S, Cummins S, Bhutia YD, Mody H, Hooks SB, Dhar S, Govindarajan R.

Cancer Lett. 2015 Apr 10;359(2):233-40. doi: 10.1016/j.canlet.2015.01.017. Epub 2015 Jan 16.

9.

Convergent regulation of neuronal differentiation and Erk and Akt kinases in human neural progenitor cells by lysophosphatidic acid, sphingosine 1-phosphate, and LIF: specific roles for the LPA1 receptor.

Callihan P, Ali MW, Salazar H, Quach N, Wu X, Stice SL, Hooks SB.

ASN Neuro. 2014 Nov 24;6(6). pii: 1759091414558416. doi: 10.1177/1759091414558416. Print 2014.

10.

Regulator of G protein signaling transcript expression in human neural progenitor differentiation: R7 subfamily regulation by DNA methylation.

Tuggle K, Ali MW, Salazar H, Hooks SB.

Neurosignals. 2014;22(1):43-51. doi: 10.1159/000362128. Epub 2014 Jun 4.

11.

Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance.

Cacan E, Ali MW, Boyd NH, Hooks SB, Greer SF.

PLoS One. 2014 Jan 27;9(1):e87455. doi: 10.1371/journal.pone.0087455. eCollection 2014.

12.

Transcriptional suppression, DNA methylation, and histone deacetylation of the regulator of G-protein signaling 10 (RGS10) gene in ovarian cancer cells.

Ali MW, Cacan E, Liu Y, Pierce JY, Creasman WT, Murph MM, Govindarajan R, Eblen ST, Greer SF, Hooks SB.

PLoS One. 2013;8(3):e60185. doi: 10.1371/journal.pone.0060185. Epub 2013 Mar 22.

13.

Sphingosine-1-phosphate signaling in neural progenitors.

Callihan P, Hooks SB.

Methods Mol Biol. 2012;874:193-200. doi: 10.1007/978-1-61779-800-9_15.

PMID:
22528449
14.

Distinct generation, pharmacology, and distribution of sphingosine 1-phosphate and dihydrosphingosine 1-phosphate in human neural progenitor cells.

Callihan P, Zitomer NC, Stoeling MV, Kennedy PC, Lynch KR, Riley RT, Hooks SB.

Neuropharmacology. 2012 Feb;62(2):988-96. doi: 10.1016/j.neuropharm.2011.10.005. Epub 2011 Oct 15.

15.

Regulation of stem cell pluripotency and differentiation by G protein coupled receptors.

Callihan P, Mumaw J, Machacek DW, Stice SL, Hooks SB.

Pharmacol Ther. 2011 Mar;129(3):290-306. doi: 10.1016/j.pharmthera.2010.10.007. Epub 2010 Nov 10. Review.

PMID:
21073897
16.

Regulators of G-Protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells.

Hooks SB, Callihan P, Altman MK, Hurst JH, Ali MW, Murph MM.

Mol Cancer. 2010 Nov 2;9:289. doi: 10.1186/1476-4598-9-289.

17.

Lubiprostone neither decreases gastric and small-bowel transit time nor improves visualization of small bowel for capsule endoscopy: a double-blind, placebo-controlled study.

Hooks SB 3rd, Rutland TJ, Di Palma JA.

Gastrointest Endosc. 2009 Nov;70(5):942-6. doi: 10.1016/j.gie.2009.04.045. Epub 2009 Jul 4.

PMID:
19577749
18.

Regulator of G-protein signaling (RGS) proteins in cancer biology.

Hurst JH, Hooks SB.

Biochem Pharmacol. 2009 Nov 15;78(10):1289-97. doi: 10.1016/j.bcp.2009.06.028. Epub 2009 Jun 25. Review.

PMID:
19559677
19.
20.

Human neural progenitors express functional lysophospholipid receptors that regulate cell growth and morphology.

Hurst JH, Mumaw J, Machacek DW, Sturkie C, Callihan P, Stice SL, Hooks SB.

BMC Neurosci. 2008 Dec 11;9:118. doi: 10.1186/1471-2202-9-118.

21.

Regulator of G-protein signalling expression and function in ovarian cancer cell lines.

Hurst JH, Mendpara N, Hooks SB.

Cell Mol Biol Lett. 2009;14(1):153-74. doi: 10.2478/s11658-008-0040-7. Epub 2008 Oct 31.

PMID:
18979070
22.

Role of Ca2+-independent phospholipase A2 in cell growth and signaling.

Hooks SB, Cummings BS.

Biochem Pharmacol. 2008 Oct 30;76(9):1059-67. doi: 10.1016/j.bcp.2008.07.044. Epub 2008 Aug 15. Review.

23.

Endogenous RGS proteins attenuate Galpha(i)-mediated lysophosphatidic acid signaling pathways in ovarian cancer cells.

Hurst JH, Henkel PA, Brown AL, Hooks SB.

Cell Signal. 2008 Feb;20(2):381-9. Epub 2007 Nov 7.

PMID:
18083345
24.

A role of RGS proteins in drug addiction.

Hooks SB, Martemyanov K, Zachariou V.

Biochem Pharmacol. 2008 Jan 1;75(1):76-84. Epub 2007 Aug 11. Review.

PMID:
17880927
25.

Club drug use among youths in treatment for substance abuse.

Hopfer C, Mendelson B, Van Leeuwen JM, Kelly S, Hooks S.

Am J Addict. 2006 Jan-Feb;15(1):94-9.

PMID:
16449098
26.
27.

The G betagamma dimer as a novel source of selectivity in G-protein signaling: GGL-ing at convention.

Jones MB, Siderovski DP, Hooks SB.

Mol Interv. 2004 Aug;4(4):200-14. Review.

PMID:
15304556
28.

Dominant-negative inhibition of pheromone receptor signaling by a single point mutation in the G protein alpha subunit.

Wu YL, Hooks SB, Harden TK, Dohlman HG.

J Biol Chem. 2004 Aug 20;279(34):35287-97. Epub 2004 Jun 14. Erratum in: J Biol Chem. 2005 Aug 19;280(33):29988.

29.

A snapshot of substance abuse among homeless and runaway youth in Denver, Colorado.

Van Leeuwen JM, Hopfer C, Hooks S, White R, Petersen J, Pirkopf J.

J Community Health. 2004 Jun;29(3):217-29.

PMID:
15141897
30.

Purification and functional reconstitution of the human P2Y12 receptor.

Bodor ET, Waldo GL, Hooks SB, Corbitt J, Boyer JL, Harden TK.

Mol Pharmacol. 2003 Nov;64(5):1210-6.

31.

RGS6, RGS7, RGS9, and RGS11 stimulate GTPase activity of Gi family G-proteins with differential selectivity and maximal activity.

Hooks SB, Waldo GL, Corbitt J, Bodor ET, Krumins AM, Harden TK.

J Biol Chem. 2003 Mar 21;278(12):10087-93. Epub 2003 Jan 16.

32.

Adolescent heroin use: a review of the descriptive and treatment literature.

Hopfer CJ, Khuri E, Crowley TJ, Hooks S.

J Subst Abuse Treat. 2002 Oct;23(3):231-37. Review.

PMID:
12392810
33.

Lysophosphatidic acid-induced mitogenesis is regulated by lipid phosphate phosphatases and is Edg-receptor independent.

Hooks SB, Santos WL, Im DS, Heise CE, Macdonald TL, Lynch KR.

J Biol Chem. 2001 Feb 16;276(7):4611-21. Epub 2000 Oct 19.

34.

Characterization of the human cysteinyl leukotriene CysLT1 receptor.

Lynch KR, O'Neill GP, Liu Q, Im DS, Sawyer N, Metters KM, Coulombe N, Abramovitz M, Figueroa DJ, Zeng Z, Connolly BM, Bai C, Austin CP, Chateauneuf A, Stocco R, Greig GM, Kargman S, Hooks SB, Hosfield E, Williams DL Jr, Ford-Hutchinson AW, Caskey CT, Evans JF.

Nature. 1999 Jun 24;399(6738):789-93.

PMID:
10391245
35.

Structure--activity relationships of lysophosphatidic acid: conformationally restricted backbone mimetics.

Hopper DW, Ragan SP, Hooks SB, Lynch KR, Macdonald TL.

J Med Chem. 1999 Mar 25;42(6):963-70.

PMID:
10090779
36.

Identification of a novel human phosphatidic acid phosphatase type 2 isoform.

Hooks SB, Ragan SP, Lynch KR.

FEBS Lett. 1998 May 8;427(2):188-92.

37.

Characterization of a receptor subtype-selective lysophosphatidic acid mimetic.

Hooks SB, Ragan SP, Hopper DW, Hönemann CW, Durieux ME, Macdonald TL, Lynch KR.

Mol Pharmacol. 1998 Feb;53(2):188-94.

39.

Effects of a take-home drug prevention program on drug-related communication and beliefs of parents and children.

Werch CE, Young M, Clark M, Garrett C, Hooks S, Kersten C.

J Sch Health. 1991 Oct;61(8):346-50.

PMID:
1787697

Supplemental Content

Support Center